Division of Cadent Therapeutics
Latest From Ataxion Inc.
A review of biopharma startup dealmaking and financing activity from January through March 2017, based on data from Strategic Transactions, showed a 19% decline in startup financing compared with the fourth quarter of 2016, but big pharmas provided capital in the form of alliance fees.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in March 2017.
North Carolina biotech may need to conduct a 9,000-patient safety study after solithromycin was rejected by FDA, but it has $231m in cash and another Phase III candidate. Apricus is clearing financial room by transferring ex-US rights to Vivaros to Ferring, while Heat is acquiring former spinout Pelican.
With the launch of AAVLife, Versant Ventures adds to its gene therapy portfolio, and people with Friedreich's ataxia can look to another program that takes aim at the rare inherited disease.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Cadent Therapeutics
- Senior Management
David Grayzel, MD, CEO
Michael Curtis, PhD, Chief Dev. Officer
- Contact Info
Phone: (617) 588-2644
400 Technology Sq.
Cambridge, MA 02139
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.